Caris Life Sciences, Stock Current Valuation
| CAI Stock | USD 24.30 0.47 1.90% |
Valuation analysis of Caris Life Sciences, helps investors to measure Caris Life's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. The Caris Life's current Enterprise Value Over EBITDA is estimated to increase to -38.9. The Caris Life's current Enterprise Value Multiple is estimated to increase to -38.9. Fundamental drivers impacting Caris Life's valuation include:
Overvalued
Today
Please note that Caris Life's price fluctuation is not too volatile at this time. Calculation of the real value of Caris Life Sciences, is based on 3 months time horizon. Increasing Caris Life's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Caris Life is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Caris Stock. However, Caris Life's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 24.3 | Real 20.9 | Hype 24.79 |
The intrinsic value of Caris Life's stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Caris Life's stock price.
Estimating the potential upside or downside of Caris Life Sciences, helps investors to forecast how Caris stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Caris Life more accurately as focusing exclusively on Caris Life's fundamentals will not take into account other important factors: Caris Life Sciences, Company Current Valuation Analysis
Caris Life's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Caris Life Current Valuation | 8.33 B |
Most of Caris Life's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Caris Life Sciences, is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Caris Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Caris Life is extremely important. It helps to project a fair market value of Caris Stock properly, considering its historical fundamentals such as Current Valuation. Since Caris Life's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Caris Life's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Caris Life's interrelated accounts and indicators.
Click cells to compare fundamentals
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Caris Life Sciences, has a Current Valuation of 8.33 B. This is 14.33% higher than that of the Trading Companies & Distributors sector and 8.57% higher than that of the Industrials industry. The current valuation for all United States stocks is 49.92% higher than that of the company.
Caris Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Caris Life's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Caris Life could also be used in its relative valuation, which is a method of valuing Caris Life by comparing valuation metrics of similar companies.Caris Life is currently under evaluation in current valuation category among its peers.
Caris Life ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Caris Life's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Caris Life's managers, analysts, and investors.Environmental | Governance | Social |
Caris Fundamentals
| Profit Margin | (0.60) % | ||||
| Operating Margin | (0.48) % | ||||
| Current Valuation | 8.33 B | ||||
| Shares Outstanding | 283.56 M | ||||
| Shares Owned By Insiders | 48.15 % | ||||
| Shares Owned By Institutions | 16.18 % | ||||
| Number Of Shares Shorted | 4.19 M | ||||
| Price To Earning | 17.74 X | ||||
| Price To Sales | 17.55 X | ||||
| Revenue | 412.26 M | ||||
| Gross Profit | 211.38 M | ||||
| EBITDA | (182.95 M) | ||||
| Net Income | (281.89 M) | ||||
| Cash And Equivalents | 38.81 M | ||||
| Cash Per Share | 2.26 X | ||||
| Total Debt | 424.26 M | ||||
| Debt To Equity | 2.41 % | ||||
| Current Ratio | 0.45 X | ||||
| Book Value Per Share | (18.45) X | ||||
| Cash Flow From Operations | (245.2 M) | ||||
| Earnings Per Share | (1.25) X | ||||
| Price To Earnings To Growth | 0.90 X | ||||
| Number Of Employees | 1.77 K | ||||
| Beta | 1.47 | ||||
| Market Capitalization | 7.94 B | ||||
| Total Asset | 343.73 M | ||||
| Retained Earnings | (2.47 B) | ||||
| Working Capital | 50.31 M | ||||
| Current Asset | 131.15 M | ||||
| Current Liabilities | 215.06 M | ||||
| Net Asset | 343.73 M | ||||
| Last Dividend Paid | 1.2 |
About Caris Life Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Caris Life Sciences,'s financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Caris Life using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Caris Life Sciences, based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Caris Life Sciences, offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Caris Life's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Caris Life Sciences, Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Caris Life Sciences, Stock:Check out Caris Life Piotroski F Score and Caris Life Altman Z Score analysis. You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Trading Companies & Distributors space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Caris Life. If investors know Caris will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Caris Life listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Caris Life Sciences, is measured differently than its book value, which is the value of Caris that is recorded on the company's balance sheet. Investors also form their own opinion of Caris Life's value that differs from its market value or its book value, called intrinsic value, which is Caris Life's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Caris Life's market value can be influenced by many factors that don't directly affect Caris Life's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Caris Life's value and its price as these two are different measures arrived at by different means. Investors typically determine if Caris Life is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Caris Life's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.